CustomVis to raise £2.4m for sales ramp-up of ophthalmic laser
This article was originally published in Clinica
Australian eye laser equipment company CustomVis is expecting to raise £2.4m ($4.7m) in a bid to grow its sales and marketing activities. The firm, listed on the UK AIM stock exchange, has issued around 73.8 million new shares, priced at 3.25p each. It said the proceeds will go towards recruiting more sales staff, expanding its manufacturing capacity, and conducting preliminary work for clinical trials in the US.
You may also be interested in...
Stephen Hahn’s low visibility period as the newly installed FDA commissioner comes to an abrupt end. Trump offers generous praise amid COVID-19 response – but how quickly might that change to blame?
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.
Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.